1)Stewart WC, Chorak RP, Hunt HH et al:Factors associated with visual loss in patients with advanced glaucomatous changes in the optic nerve head. Am J Ophthalmol 116:176-181, 1993
2)Thai JC:A comprehensive perspective on patient adherence to topical glaucoma therapy. Ophthalmology 116(Suppl):S30-36, 2009
3)Sleath B, Blalock S, Covert D, Stone JL et al:The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity. Ophthalmology 118:2398-2402, 2011
4)Taylor SA, Galbraith SM, Mills RP:Causes of non-compliance with drug regimens in glaucoma patients:a qualitative study. J Ocul Pharmacol Ther 18:401-409, 2002
5)Hennessy AL, Katz J, Covert D et al:A video study of drop instillation in both glaucoma and retina patients with visual impairment. Am J Ophthalmol 152:982-988, 2011
6)Kahook MY:Developments in dosing aids and adherence devices for glaucoma therapy:current and future perspectives. Exper Rev Med Devices 4:261-266, 2007
7)Stack RR, Mckellar MJ:Black eye drop bottle tips improve compliance. Clin Experiment Ophthalmol 32:39-41, 2004
8)Friedman DS, Jampel HD, Congdon NG et al:The Travatan dosing aid accurately records when drops are taken. Am J Ophthalmol 143:699-701, 2007
9)Okeke CO, Quigley HA, Jampel HD et al:Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study. Ophthalmology 116:191-199, 2009
10)Semes L, Shaikh AS:Evaluation of the Xal-Ease latanoprost delivery system. Optometry 78:30-33, 2007
11)Nordmann JP, Baudouin C, Bron A et al:Xal-Ease:impact of an ocular hypotensive delivery device on ease of eyedrop administration, patient compliance, and satisfaction. Eur J Ophthalmol 19:949-956, 2009
12)日本緑内障学会(編).緑内障ガイドライン.日眼会誌 110:778-814,2006
13)小林 博・岩切 亮・小林かおり・他:緑内障患者の点眼状況.臨眼 60:43-47,2006